⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMO News
Sangamo Therapeutics, Inc. Common Stock
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
globenewswire.com
SGMO
Form 8-K
sec.gov
SGMO
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
globenewswire.com
SGMO
Form 8-K
sec.gov
SGMO
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
globenewswire.com
SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
globenewswire.com
SGMO
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
globenewswire.com
SGMO
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
globenewswire.com
SGMO